美国FDA药品溶出方法数据库

药品通用名称	剂型	USP溶出装置	速度	溶出介质	介质体积	建议取样时间（分钟）	更新日期
Thalidomide	Capsule	II (Paddle)	100	1.5% (w/v) SLS (pH 3.0, adj w/ HCl)	900	10, 20, 30, 60 and 90	2006/03/04
Theophylline	Capsule (Extended Release)			Refer to USP	900		2008/10/06
Theophylline (100 mg and 200 mg)	Tablet (Extended Release)	II (Paddle)	50	SGF without Enzyme, pH 1.2 during 1st hour. Phosphate Buffer at pH 7.5 from end of hour 1 through the duration of testing	900	1, 4, 8, 12 hours	2008/10/06
Theophylline (300 mg and 450 mg)	Tablet (Extended Release)	II (Paddle)	50	SGF without Enzyme, pH 1.2 during 1st hour. Phosphate Buffer at pH 7.5 from end of hour 1 through the duration of testing	900	1, 4, 8, 12 hours	2008/10/06
Theophylline (600 mg and 400 mg)	Tablet (Extended Release)	I (Basket)	100	SGF without enzyme, pH 1.2 during 1st hour. SIF without enzyme from end of hour 1 through the duration of the testing	900	1, 2, 4, 8, 12 and 24 hours	2008/10/06
Thioguanine	Tablet			Develop a dissolution method			2024/01/03
Tiagabine HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Ticagrelor	Tablet			Develop a dissolution method			2023/09/15
Ticlopidine HCl	Tablet			Develop a dissolution method			2023/09/15
Timolol Maleate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Tinidazole	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Tiopronin	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Tiopronin	Tablet (Delayed Release)	I (Basket)	100	Acid Stage: 0.1 N HCl; Buffer Stage: 50 mM Potassium phosphate, pH 6.8	Acid Stage: 900; Buffer Stage: 900	Acid Stage:120; Buffer Stage:10, 20, 30, 45 and 60	2022/07/07
Tipiracil HCl/Trifluridine	Tablet	II (Paddle)	50	0.1 N HCl	900	5, 10, 15, 20 and 30	2017/11/02
Tipranavir	Capsule	II (Paddle)	50	0.05 M phosphate buffer pH 6.8	900	15, 30, 45 and 60	2007/12/03
Tivozanib HCl	Capsule	II (Paddle with sinker)	50	Tier I: 0.1 mM HCI with 0.5% (w/v) sodium dodecyl sulfate (SDS) (900 mL); Tier II: 0.1 mM HCI with pepsin (as per USP) (750 mL) for the first 10 minutes, followed by addition of 0.1 mM HCI with SDS (3% w/v) (150 mL) for the remainder of the dissolution	900	5, 10, 15, 20 and 30	2023/02/09
Tizanidine HCl	Capsule			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Tizanidine HCl	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Tofacitinib Citrate	Tablet			Refer to FDA's Dissolution Guidance, 2018			2020/07/02
Tofacitinib Citrate	Tablet (Extended Release)	II (Paddle) with option to use a sinker	50	Phosphate Buffer, pH 6.8	900	1, 1.5, 2, 2.5, 3, 4, 6 and 8 hours	2016/07/28